Dogwood Therapeutics, Inc. Business Combination, Acquisition Related Costs
Dogwood Therapeutics, Inc. (DWTX) reported Business Combination, Acquisition Related Costs of $1.03 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2024-11-08
- Dogwood Therapeutics, Inc. business combination, acquisition related costs for the quarter ending 2024-09-30 was $1.03M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 9 month |
|---|---|---|
| 2024-09-30 | $1.03M 10-Q · filed 2024-11-08 | $1.03M 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |